The Pathologist / Issues / 2025 / September / MYCN Amplification Predicts Poor Outcomes in Gliomas / Notecards
Oncology Research and Innovations Omics

MYCN Amplification Predicts Poor Outcomes in Gliomas

Raised levels of proto-oncogene MYCN predict higher grade, epithelioid features, and reduced survival

By Kathryn Wighton 10/01/2025 News 2 min read

Share

0

  1. Study published in The Journal of Pathology Clinical Research.

  2. Analysed 190 patients with IDH-mutant gliomas.

  3. MYCN amplification found in 14.7 percent of cases.

  4. Amplification linked to shorter survival.

  5. Proposed reclassification of lower-grade gliomas with MYCN amplification as grade

1

  • Kaplan–Meier and Cox regression used for survival analysis.

  • Histological features included eosinophilic cytoplasm and necrosis.

    • About the Author(s)

    Kathryn Wighton

    Editor, Conexiant

    More Articles by Kathryn Wighton

    Explore More in Pathology

    Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

    Recommended